Literature DB >> 2265473

Role of cholecystokinin in the development of BOP-induced pancreatic lesions in hamsters.

M Meijers1, A van Garderen-Hoetmer, C B Lamers, L C Rovati, J B Jansen, R A Woutersen.   

Abstract

Cholecystokinin (CCK) has been shown to promote pancreatic growth and azaserine-induced pancreatic carcinogenesis in rats. The present study was carried out to determine effects of CCK on pancreatic growth and carcinogenesis in the N-nitrosobis(2-oxopropyl)amine (BOP) hamster model. One hundred male Syrian golden hamsters were injected s.c. once weekly with 20 mg BOP/kg body wt at 6, 7 and 8 weeks of age, and divided into four groups of 25 animals each, which received one of the following treatments (once daily, 3 days/week for 16 weeks): gelatin; CR-1409, a potent CCK-receptor antagonist; CCK-8, 2.5 micrograms/kg body wt; or CCK-8 in combination with CR-1409 (30 min before CCK treatment). The animals were killed after 19 weeks. The growth of the pancreas but not the incidence of pancreatic (pre)neoplastic lesions was enhanced by CCK-8. CR-1409 did not influence the effect of CCK on pancreatic growth.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2265473     DOI： 10.1093/carcin/11.12.2223

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN： 0143-3334            Impact factor:   4.944


  10 in total

1.  The impact of laparoscopic biopsy of pancreatic lymph nodes with helium and carbon dioxide on port site and liver metastasis in BOP-induced pancreatic cancer in hamster.

Authors:  F A Wenger; C A Jacobi; M Kilian; H Dressler; H Guski; J M Müller
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 2.  On the role of cholecystokinin in pancreatic cancer.

Authors:  M K Herrington; T E Adrian
Journal:  Int J Pancreatol       Date:  1995-04

3.  Impact of taurolidin and octreotide on liver metastasis and lipid peroxidation after laparoscopy in chemical induced ductal pancreatic cancer.

Authors:  Maik Kilian; Jan Ilga Gregor; Ina Heukamp; Chris Braumann; Hans Guski; Ingolf Schimke; Martin Karl Walz; Christoph Andreas Jacobi; Frank Axel Wenger
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

Review 4.  Hormonal therapy of pancreatic carcinoma. Rationale and perspectives.

Authors:  D Perilli; C Mansi; V Savarino; G Celle
Journal:  Int J Pancreatol       Date:  1993-06

5.  Effects of orchiectomy, alone or in combination with testosterone, and cyproterone acetate on exocrine pancreatic carcinogenesis in rats and hamsters.

Authors:  M Meijers; C J Visser; J G Klijn; S W Lamberts; A van Garderen-Hoetmer; F H de Jong; J A Foekens; R A Woutersen
Journal:  Int J Pancreatol       Date:  1992-04

6.  Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.

Authors:  F A Wenger; M Kilian; M Bisevac; C Khodadayan; M von Seebach; I Schimke; H Guski; J M Müller
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  Enhancement of biliary carcinogenesis in hamsters by cholecystokinin.

Authors:  Y Ikematsu; T Tomioka; Y Tajima; T Tsunoda; T Kanematsu
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

8.  Impact of Octreotide and SOM-230 on liver metastasis and hepatic lipidperoxidation in ductal pancreatic adenocarcinoma in Syrian Hamster.

Authors:  M Kilian; J I Gregor; I Heukamp; K Helmecke; M Hanel; B Wassersleben; M K Walz; I Schimke; G Kristiansen; F A Wenger
Journal:  Clin Exp Metastasis       Date:  2009-06-12       Impact factor: 5.150

9.  Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats.

Authors:  M J Appel; M Meijers; A Van Garderen-Hoetmer; C B Lamers; L C Rovati; D Sprij-Mooij; J B Jansen; R A Woutersen
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

10.  Expression of receptors for gut peptides in human pancreatic adenocarcinoma and tumour-free pancreas.

Authors:  C Tang; I Biemond; G J Offerhaus; W Verspaget; C B Lamers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.